Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | BRD2 | P25440 | 4/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370551 | 0.81 | BRD4 (0.38) | BRD4BRD2BRD3BRDTABCB1 | |
| SCHEMBL4183869 | 0.81 | BRD4 (0.48) | BRD4SLC6A2SLC6A4BRD2BRD3 | |
| SCHEMBL347749 | 0.72 | BRD4 (0.58) | BRD4BRD2BRD3BRDTABCB1 | |
| SCHEMBL348377 | 0.71 | XDH (0.51) | BRD4ABCB1KDM4EALDH1A1LMNA | |
| SCHEMBL348539 | 0.71 | BRD4 (0.49) | BRD4BRD2BRD3BRDTABCB1 | |
| SCHEMBL4176435 | 0.70 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3KDM4EALDH1A1 | |
| SCHEMBL348840 | 0.68 | BRD4 (0.52) | BRD4BRD2BRD3BRDTMEN1 | |
| SCHEMBL370550 | 0.67 | BRD4 (0.56) | BRD4BRD2BRD3BRDT | |
| SCHEMBL11826604 | 0.62 | XDH (0.58) | ABCB1KDM4EALDH1A1LMNAGAA | |
| SCHEMBL26079993 | 0.60 | ABCB1 (0.80) | BRD4BRD2BRD3BRDTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | BRD4 1004/4885SLC6A2 1466/4885SLC6A4 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.